These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

682 related items for PubMed ID: 15865231

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Clinical impact of the M184V mutation on switching to didanosine or maintaining lamivudine treatment in nucleoside reverse-transcriptase inhibitor-experienced patients.
    Winters MA, Bosch RJ, Albrecht MA, Katzenstein DA, AIDS Clinical Trials Group 364 Study Team.
    J Infect Dis; 2003 Aug 15; 188(4):537-40. PubMed ID: 12898440
    [Abstract] [Full Text] [Related]

  • 23. Immunological recovery despite virological failure is independent of human immunodeficiency virus-type 1 resistant mutants in children receiving highly active antiretroviral therapy.
    Chiappini E, Galli L, Zazzi M, de Martino M.
    J Med Virol; 2003 Aug 15; 70(4):506-12. PubMed ID: 12794711
    [Abstract] [Full Text] [Related]

  • 24. Different outcomes in patients achieving complete or partial viral load suppression on antiretroviral therapy.
    de Mendoza C, Soriano V, Pérez-Olmeda M, Rodés B, Casas E, González-Lahoz J.
    J Hum Virol; 1999 Aug 15; 2(6):344-9. PubMed ID: 10774551
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Evaluation of minority populations of HIV type-1 with K103N and M184V drug resistance mutations among children in Argentina.
    Vignoles M, Barboni G, Agosti MR, Quarleri J, García MK, Ayala SG, Salomón H.
    Antivir Ther; 2009 Aug 15; 14(8):1175-81. PubMed ID: 20032547
    [Abstract] [Full Text] [Related]

  • 27. Antiretroviral treatment outcome following genotyping in Thai children who failed dual nucleoside reverse transcriptase inhibitors.
    Bunupuradah T, Suntarattiwong P, Li A, Sirivichayakul S, Pancharoen C, Boonrak P, Puthanakit T, Kerr SJ, Ruxrungtham K, Chotpitayasunondh T, Hirschel B, Ananworanich J, HIV-NAT 013 Study Team.
    Int J Infect Dis; 2010 Apr 15; 14(4):e311-6. PubMed ID: 19699673
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Impact of genotypic resistance testing on selection of salvage regimen in clinical practice.
    Haupts S, Ledergerber B, Böni J, Schüpbach J, Kronenberg A, Opravil M, Flepp M, Speck RF, Grube C, Rentsch K, Weber R, Günthard HF, Swiss HIV Cohort Study.
    Antivir Ther; 2003 Oct 15; 8(5):443-54. PubMed ID: 14640392
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Positive virological outcome after lopinavir/ritonavir salvage therapy in protease inhibitor-experienced HIV-1-infected children: a prospective cohort study.
    Resino S, Bellón JM, Ramos JT, Gonzalez-Rivera M, de José MI, González MI, Gurbindo D, Mellado MJ, Cabrero E, Muñoz-Fernández MA.
    J Antimicrob Chemother; 2004 Nov 15; 54(5):921-31. PubMed ID: 15472006
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort.
    Tozzi V, Zaccarelli M, Narciso P, Trotta MP, Ceccherini-Silberstein F, De Longis P, D'Offizi G, Forbici F, D'Arrigo R, Boumis E, Bellagamba R, Bonfigli S, Carvelli C, Antinori A, Perno CF.
    J Infect Dis; 2004 May 01; 189(9):1688-95. PubMed ID: 15116307
    [Abstract] [Full Text] [Related]

  • 39. Immunovirologic consequences and safety of short, non-structured interruptions of successful antiretroviral treatment.
    Sanchez R, Portilla J, Gimeno A, Boix V, Llopis C, Sanchez-Paya J, Merino E, de la Sen ML, Muñoz C, Reus S, Plazas J.
    J Infect; 2007 Feb 01; 54(2):159-66. PubMed ID: 16690132
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 35.